Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines.: HP5-142/1-2022E-1-PDF ; HP5-142/2-2022E-1-PDF
"On June 29, 2022, NACI published interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. The statement outlined recommendations for booster doses in specific populations ahead of the uncertain trajectory of the COVID-19 pandemic in the coming months"--Background, page 3.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.915979&sl=0
| Department/Agency | Public Health Agency of Canada, issuing body. |
|---|---|
| Title | Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Earlier edition | Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines. |
| Format | Electronic |
| Electronic document |
|
| Note(s) | Issued also in French under title: Recommandations sur l'utilisation des vaccins à ARNm bivalents contre la COVID-19 contenant le variant Omicron. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). "Updated: October 7, 2022." Includes bibliographical references (pages 17-22). |
| Publishing information | Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, September 1, 2022. ©2022 |
| Description | 1 online resource (27 pages) + 1 summary (8 pages) |
| ISBN | 9780660457246 9780660457253 |
| Catalogue number |
|
| Subject terms | COVID-19 (Disease) -- Vaccination -- Canada. COVID-19 vaccines -- Canada. |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: